what is in glutathione and why must we protect patient access to it? Immunocal Glutathione Precursor – Supports

Every Sunday I write these notes

In Embodiment 3 of this disclosure are compounds of Formula I, or any one of Embodiments 1-2, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is In Embodiment 4 of this disclosure are compounds of Formula I, or any one of Embodiments 1-3 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is phenyl substituted with a substituent selected from: hydroxy, halogen CN, C 1-3 alkyl, C 1-3 alkyl-CN, OC 1-3 alkyl-CN, C 1-3 haloalkyl, C 3-6 cycloalkyl, OC 1-3 alkyl, OC 1-3 haloalkyl, O-cyclopropyl, 5 membered heteroaryl containing 2 nitrogen atoms, S(O) 2 C 1-3 alkyl, S(O) 2 NHC 1-3 alkyl, or C 1-3 alkylNH 2 , and wherein the cycloalkyl moiety is optionally further substituted with F, CH 3 , CF 3 , CN, or OH

Yang et al., 2006)

This modification stimulates the binding of Hif1a and the VHL ubiquitin ligase, which results in the subsequent degradation of Hif1a in proteasomes 102